{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 19 October 2007\line \line {\b European 
licence for Roche HIV drug Viracept re-established by European Commission} \line Roche 
ready to start re-supply of HIV medicine\line \line Roche announced today that the 
European Commission (EC) has re-instated the Viracept marketing authorization following its suspension 
earlier this summer. Roche welcomes the news and fully intends to re-supply Viracept (nelfinavir) as 
soon as possible. The timing of the re-introduction will vary from country to country and it is likely 
to be a few months before it is fully available again to prescribers and patients.\line \line \u8220?We 
are pleased that the marketing authorisation for Viracept has been re-instated in Europe.\u8221? said William 
M. Burns, CEO of Roche\u8217?s Pharmaceutical Division \u8220?Our teams have worked diligently in manufacturing 
and in close collaboration with the health authorities, health care providers, NGO treatment providers 
and patient groups on the recall with the full intention of re-supplying this medication.\u8221? \line \line Viracept\u8217?s 
license was suspended in August this year following the discovery that some of the drug batches contained 
a substance called ethyl mesylate sulphonate (EMS).\line \line {\b About 
Viracept} \line Viracept (nelfinavir), a protease inhibitor is supplied by Roche outside 
the US, Canada and Japan. Viracept was first introduced by Roche in 1999. \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world\u8217?s 
biggest biotech company and an innovator of products and services for the early detection, prevention, 
diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and 
transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune 
diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals 
Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion 
Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances 
with numerous partners, including majority ownership interests in Genentech and Chugai. Roche\u8217?s Diagnostics 
Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products 
and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further 
information, please visit our website at www.roche.com (http://www.roche.com). \line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\line \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}